PDL BioPharma Reports 2019 Third Quarter Financial Results

INCLINE VILLAGE, Nev., Nov. 6, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) reports financial results for the three and nine months ended September 30, 2019:

Third Quarter Financial Highlights

    --  Total revenues were $44.2 million, including $20.3 million in product
        revenue and $23.9 million in revenue from royalty rights - change in
        fair value.
    --  LENSAR revenues were $8.1 million, up 22% over the prior-year period.
    --  U.S. market share for branded Tekturna and authorized generic of
        Tekturna remained steady at approximately 73%.
    --  Net cash royalties from all royalty rights were $25.6 million, up from
        $19.1 million in the prior-year period.
    --  GAAP net loss was $17.8 million. Non-GAAP net income was $10.4 million.
        A reconciliation of GAAP to non-GAAP financial results can be found in
        Table 3 at the end of this news release.
    --  Completed $100 million share repurchase program by repurchasing 1.3
        million shares of common stock in the open market for $4.1 million.

"Third quarter revenues exceeded $44 million driven by continued growth from the LENSAR Laser System and strong contributions from our royalty assets, both of which are tracking ahead of our previous guidance range," said Dominique Monnet, president and CEO of PDL. "LENSAR's quarterly revenues reached a record $8 million, up 22% over the prior-year period and up 27% year-to-date. Through PDL-funded R&D investments, LENSAR has continued to advance its best-in-class technology for the treatment of cataracts and the management of astigmatism. LENSAR's technology benefits have been increasingly recognized by ophthalmic surgeons, as indicated by steady and robust year-over-year procedure volume growth since the product was launched in mid-2012. Procedure volume for the first nine months of 2019 is on pace to continue this trend.

"We are also pleased with progress at Evofem Biosciences, which is on track to resubmit the Amphora(®) NDA in the fourth quarter," he added. "Given this timeframe, we anticipate Amphora's commercial launch for the prevention of pregnancy in 2020, subject to FDA approval. We believe our strategic investment in Evofem allows our shareholders to benefit from the significant near-term and longer-term commercial potential of Amphora. It may also present a strategic position for PDL's potential expansion into the underserved women's health market.

"We completed our $100 million share buy-back program during the third quarter, which represents the Company's largest single investment year-to-date. We are also continuing our efforts to reduce our operating expenses, with general and administrative expenses (G&A) down 16% year-to-date."

Revenue Highlights

    --  Total third quarter revenues were $44.2 million and included $20.3
        million in product revenue and $23.9 million in revenue from royalty
        rights - change in fair value.
        --  Product revenue from the LENSAR Laser System was $8.1 million, a 22%
            increase from the third quarter of 2018. Revenue generated outside
            the U.S. accounted for the majority of the revenue increase. LENSAR
            procedure volume for the third quarter of 2019 increased 28% from
            the prior-year period.
        --  Product revenue from Noden was $12.2 million compared with $17.8
            million in the prior-year period. Revenue was split evenly between
            the U.S. and rest of the world at $6.1 million, compared with $9.7
            million and $8.0 million, respectively, in the prior-year period.
            The U.S. market share for branded Tekturna and the authorized
            generic of Tekturna was 73%, relatively unchanged from the second
            quarter of 2019.
        --  Net royalty revenues from acquired royalty rights, which include
            cash royalties received and a change in fair value of the royalty
            rights assets, were $23.9 million compared with $42.2 million in the
            prior-year period. The decrease in royalty revenue is primarily
            related to the increase in fair value in the prior year period that
            resulted from the acquisition of additional Glumetza(®) royalty
            rights from Assertio Therapeutics in that period. PDL received $25.6
            million in net cash royalties from all of its royalty rights in the
            third quarter of 2019, up from $19.1 million in the year-ago
            quarter.
    --  Total revenues for the first nine months of 2019 were $60.6 million and
        included $64.9 million in product revenue and negative $4.3 million in
        revenue from royalty rights - change in fair value.
        --  Product revenue from the LENSAR Laser System was $22.2 million, a
            27% increase from the prior-year period. Revenue generated outside
            of the U.S. accounted for the majority of the increase. LENSAR
            procedure volume for the first nine months of 2019 increased 30%
            from the prior-year period.
        --  Product revenue from the Noden Products was $42.6 million compared
            with $62.0 million for the prior-year period. Sales for the first
            nine months of 2019 were comprised of $21.0 million in the U.S. and
            $21.6 million in the rest of the world, compared with $30.6 million
            and $31.4 million, respectively, in the prior-year period. The
            decline in sales of branded Tekturna in the U.S. is due primarily to
            the launch of an authorized generic of Tekturna in the U.S. and the
            launch of a third-party generic of aliskiren late in the first
            quarter of 2019. The decline in sales in the rest of the world is
            due to lower sales volume of Rasilez in certain territories, in part
            reflecting additional measures to maximize product profitability.
        --  Revenue from royalty rights - change in fair value was negative $4.3
            million for the first nine months of 2019, compared with $66.1
            million in the prior-year period. The decrease is primarily related
            to a non-cash adjustment to the AcelRx royalty asset fair value of
            negative $60.0 million in the second quarter of 2019. PDL received
            $58.3 million in net cash royalties from its royalty rights in the
            first nine months of 2019.
        --  Interest revenue decreased by $2.3 million from the prior-year
            period due to modifications to the Company's agreement with CareView
            Communications, which deferred interest payments for the first nine
            months of 2019.
        --  Royalties from PDL's licensees to the Queen et al. patents were less
            than $0.1 million for the first nine months of 2019, compared with
            $4.5 million for the prior-year period, reflecting the runout of the
            royalties on the sales of Tysabri(®).

Operating Expense Highlights

    --  Operating expenses for the third quarter of 2019 were $34.7 million, a
        $3.6 million increase from the third quarter of 2018. The increase was
        primarily due to a $3.6 million increase in research and development
        (R&D) expenses associated with product development and patent licensing
        for LENSAR, and a $3.1 million, or 26%, increase in cost of product
        revenue, $2.4 million of which related to a termination provision in a
        Noden supply agreement amended in June 2019 involving end of contract
        fees, most of which were incurred in the third quarter of 2019. These
        increases were partially offset by a $1.1 million, or 8%, decline in G&A
        expenses, primarily due to lower professional fees, and a $1.8 million,
        or 51%, decline in sales and marketing expenses reflecting savings from
        the change in the Company's marketing strategy for the Noden Products.
    --  Operating expenses for the first nine months of 2019 were $90.6 million,
        a $146.5 million decrease from the prior-year period. The decrease was
        primarily a result of the net impact of: the $152.3 million impairment
        of the Noden Products intangible assets in the second quarter of 2018
        and related reductions to the Noden Products contingent liability and
        amortization expense associated with those intangible assets which, in
        aggregate, accounted for $139.1 million of the decrease; a $6.4 million,
        or 16%, decline in G&A expenses primarily due to lower professional and
        asset management fees; and a $7.9 million, or 55%, decline in sales and
        marketing expenses reflecting savings from the change in the Company's
        marketing strategy for the Noden Products. These decreases were
        partially offset by an increase in R&D expenses of $3.9 million
        associated with product development and patent licensing for LENSAR.

Other Financial Highlights

    --  On a GAAP basis, the net loss attributable to PDL's shareholders for the
        third quarter of 2019 was $17.8 million, or $0.16 per share, compared
        with GAAP net income attributable to PDL's shareholders of $25.6
        million, or $0.18 per share on a diluted basis, for the prior-year
        period. Noteworthy items reflected in the third quarter net loss include
        pre-tax charges of $3.9 million for the convertible debt exchange, a
        $3.6 million increase to R&D expense, primarily the result of the
        acquisition of LENSAR intellectual property, a $2.4 million
        manufacturing charge for our Noden products and a $27.4 million loss due
        to the decrease in fair value of our investment in Evofem, partially
        offset by a $3.5 million gain recognized for the sale of intangible
        assets. Non-GAAP net income attributable to PDL's shareholders was $10.4
        million for the third quarter of 2019, compared with non-GAAP net income
        of $13.1 million for the third quarter of 2018.
    --  The GAAP net loss attributable to PDL's shareholders for the first nine
        months of 2019 was $15.5 million, or $0.13 per share, compared with a
        GAAP net loss attributable to PDL's shareholders of $85.1 million or
        $0.58 per share, for the prior-year period. Non-GAAP net income
        attributable to PDL's shareholders was $34.9 million for the first nine
        months of 2019, compared with non-GAAP net income of $44.2 million for
        the prior-year period.
    --  PDL had cash and cash equivalents of $294.3 million as of September 30,
        2019, compared with cash and cash equivalents of $394.6 million as of
        December 31, 2018.
    --  The $100.3 million reduction in cash and cash equivalents during the
        first nine months of 2019 was primarily the result of common stock
        repurchases of $75.9 million, the Company's investment in Evofem
        Biosciences of $60.0 million and costs incurred in the exchange of
        convertible debt of $11.1 million, which extended the maturity date of
        $86.1 million of our notes to December 2024, and net cash used in
        operations of $13.3 million. This was partially offset by the proceeds
        from royalty rights of $58.1 million and cash proceeds from the sale of
        intangible assets of $5.0 million.

Stock Repurchase Programs

    --  In November 2018 PDL began repurchasing shares of its common stock in
        the open market pursuant to the
    --  $100.0 million share repurchase program authorized by the Company's
        board of directors in September 2018.
    --  During the third quarter of 2019, the Company completed the stock
        repurchase program by repurchasing 1.3 million shares for an aggregate
        purchase price of $4.1 million.
    --  Since initiating its first stock repurchase program in March 2017, the
        Company has repurchased 53.1 million shares for $155.0 million, at an
        average cost of $2.92 per share.
    --  As of October 31, 2019, the Company had approximately 114.2 million
        shares of common stock outstanding.

Financial Guidance

    --  PDL is affirming 2019 financial guidance for Noden product revenue,
        which is expected to be in the range of $50 million to $55 million.
    --  PDL now expects 2019 LENSAR product revenue to exceed $29 million and
        2019 cash royalties to exceed $65 million. This compares with previous
        guidance for LENSAR product revenue, which was expected to be in the
        range of $27 million to $29 million, and cash royalties expected to be
        in the range of $60 million to $65 million.

Conference Call and Webcast

PDL will hold a conference call to discuss financial results and provide a business update at 4:30 p.m. Eastern time today. Slides to accompany the conference call will be available in the Investor Relations section of www.pdl.com.

To access the live conference call via phone, please dial 844-535-4071 from the U.S. and Canada or 706-679-2458 internationally. The conference ID is 3195828. A telephone replay will be available beginning approximately one hour after the call through one week following the call, and can be accessed by dialing 855-859-2056 from the U.S. and Canada or 404-537-3406 internationally. The replay passcode is 3195828.

To access the live and subsequently archived webcast of the conference call, go to the Investor Relations section of www.pdl.com and select "Events & Presentations."

About PDL BioPharma, Inc.

PDL's mission is to improve the lives of patients and create value for our shareholders and our people by applying our capital and expertise for the successful development and commercialization of innovative therapeutics by our partner companies. We deliver on our mission by entering into strategic transactions involving innovative late clinical-stage or early commercial-stage therapeutics with attractive revenue growth potential. For more information please visit www.pdl.com

NOTE: PDL, PDL BioPharma, the PDL logo and associated logos and the PDL BioPharma logo are trademarks or registered trademarks of, and are proprietary to, PDL BioPharma, Inc. which reserves all rights therein. Noden, Noden Pharma, Tekturna, Tekturna HCT, Rasilez and Rasilez HCT and associated logos are trademarks or registered trademarks of, and are proprietary to, Noden Pharma DAC, which reserves all right therein. LENSAR and associated logos are trademarks or registered trademarks of, and are proprietary to, LENSAR, Inc., which reserves all rights therein.

Forward-looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from those, express or implied, in these forward-looking statements. Important factors that could impair the value of the Company's assets and business are disclosed in the risk factors contained in the Company's Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 15, 2019 and subsequent filings. All forward-looking statements are expressly qualified in their entirety by such factors. We do not undertake any duty to update any forward-looking statement except as required by law.


                                                                                             
            
              TABLE 1

                                                                                       
            
              PDL BIOPHARMA, INC.

                                                                      
            
              CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS DATA

                                                                            
            
              (In thousands, except per share amounts)




                                                                   Three Months Ended                     
            
              Nine Months Ended
                                                             September 30,                                             September 30,


                                                       2019                            2018                      2019                            2018




     
              Revenues



     Product revenue, net                                    $
            20,345                                         $
            24,387                  $
        64,868      $
         79,472


      Royalty rights -change in fair
       value                                         23,865                                      42,184                                      (4,277)           66,117


      Royalties from Queen et al.
       patents                                                                                     533                                            9             4,534



     Interest revenue                                                                             754                                                         2,254



     License and other                                (45)                                         40                                         (48)              614



     Total revenues                                 44,165                                      67,898                                       60,552           152,991





                 Operating Expenses


      Cost of product revenue,
       (excluding intangible
       amortization and impairment)                  15,033                                      11,926                                       40,191            37,016


      Amortization of intangible assets               1,575                                       1,577                                        4,745            14,254


      General and administrative                     12,092                                      13,211                                       33,037            39,401



     Sales and marketing                             1,712                                       3,469                                        6,515            14,367



     Research and development                        4,310                                         672                                        6,065             2,149


      Impairment of intangible assets                                                                                                                       152,330


      Change in fair value of contingent
       consideration                                                                               302                                                      (22,433)



     Total operating expenses                       34,722                                      31,157                                       90,553           237,084


                 Operating income (loss)              9,443                                      36,741                                     (30,001)         (84,093)





                 Non-operating (expense) income,
                  net


      Interest and other income, net                  1,460                                       1,581                                        4,984             4,871



     Interest expense                              (3,011)                                    (2,866)                                     (8,950)          (9,262)


      Equity affiliate -change in fair
       value                                       (27,378)                                                                                 18,109


      Gain on sale of intangible assets               3,476                                                                                   3,476


      Loss on exchange of convertible
       notes                                        (3,900)                                                                                (3,900)


      Total non-operating (expense)
       income, net                                 (29,353)                                    (1,285)                                      13,719           (4,391)





      (Loss) income before income taxes            (19,910)                                     35,456                                     (16,282)         (88,484)


      Income tax (benefit) expense                  (1,944)                                      9,900                                        (419)          (3,346)



                 Net (loss) income                                    (17,966)                                                  25,556                      (15,863)          (85,138)


      Less: net loss attributable to
       noncontrolling interests                       (182)                                                                                  (340)



                 Net (loss) income attributable to
                  PDL's shareholders                        $
            (17,784)                                        $
            25,556                $
        (15,523)   $
         (85,138)





                 Net (loss) income per share



     Basic                                                   $
            (0.16)                                          $
            0.18                  $
        (0.13)     $
         (0.58)




     Diluted                                                 $
            (0.16)                                          $
            0.18                  $
        (0.13)     $
         (0.58)





      Shares used to compute income per
       basic share                                  112,986                                     143,171                                      119,966           147,159



      Shares used to compute income per
       diluted share                                112,986                                     144,224                                      119,966           147,159


                                        
           
                TABLE 2

                                  
           
                PDL BIOPHARMA, INC.

                                
     
             CONDENSED CONSOLIDATED BALANCE SHEET DATA

                                      
           
                (Unaudited)

                                    
           
                (In thousands)




                                              September 30,                                  December 31,


                                                       2019                           2018



      Cash and cash equivalents                               $
              294,270                        $
      394,590


      Notes receivable                                         $
              64,008                         $
      63,813


      Royalty rights -at fair
       value                                                  $
              313,943                        $
      376,510


      Investment in equity
       affiliate                                               $
              67,200          
             $



     Total assets                                            $
              865,145                        $
      963,736


      Total convertible notes
       payable                                                $
              132,484                        $
      124,644


      Total stockholders'
       equity                                                 $
              637,434                        $
      729,779


                                                                                                   
              
                TABLE 3

                                                                                             
              
                PDL BIOPHARMA, INC.

                                                                                       
              
                GAAP to NON-GAAP RECONCILIATION:

                                                                                              
              
                NET (LOSS) INCOME

                                                                                                 
              
                (Unaudited)

                                                                                                
              
                (In thousands)





     A reconciliation between net (loss) income on a GAAP basis and on a non-GAAP basis is as follows:




                                                                           Three Months Ended                                           Nine Months Ended


                                                     
              
                September 30,                       
              
                September 30,


                                                         2019                                2018                      2019                              2018



      GAAP net (loss) income attributed to
       PDL's stockholders as reported                           $
              (17,784)                                        $
              25,556                $
        (15,523)   $
        (85,138)


      Adjustments to Non-GAAP net income
       (as detailed below)                             28,157                                        (12,429)                                        50,391           129,354


      Non-GAAP net income attributed to
       PDL's stockholders                                         $
              10,373                                         $
              13,127                  $
        34,868     $
         44,216






     An itemized reconciliation between net (loss) income on a GAAP basis and on a non-GAAP basis is as follows:




                                                                           Three Months Ended                                           Nine Months Ended


                                                     
              
                September 30,                       
              
                September 30,


                                                         2019                                2018                      2019                              2018



      GAAP net (loss) income attributed to
       PDL's stockholders, as reported                          $
              (17,784)                                        $
              25,556                $
        (15,523)   $
        (85,138)




     Adjustments:


      Mark-to-market adjustment to fair
       value - royalty assets                           1,699                                        (23,128)                                        62,567           (9,068)


      Mark-to-market adjustment to equity
       affiliate - common stock                        21,333                                                                                      (16,574)



     Non-cash interest revenues                                                                        (79)                                                          (229)


      Non-cash stock-based compensation
       expense                                          2,059                                           2,596                                          5,403             4,814


      Non-cash debt offering costs                      1,900                                           1,834                                          5,776             5,745


      Non-cash depreciation and
       amortization expense                               646                                           1,033                                          2,295             3,061


      Mark-to-market adjustment on
       warrants held                                    6,090                                            (40)                                       (1,487)            (114)


      Impairment of intangible assets                                                                                                                               152,330


      Non-cash amortization of intangible
       assets                                           1,575                                           1,577                                          4,745            14,254


      Mark-to-market adjustment of
       contingent consideration                                                                          302                                                        (22,433)


      Income tax effect related to above
       items                                          (7,145)                                          3,476                                       (12,334)         (19,006)




     Total adjustments                                28,157                                        (12,429)                                        50,391           129,354




     Non-GAAP net income                                         $
              10,373                                         $
              13,127                  $
        34,868     $
         44,216

Use of Non-GAAP Financial Measures

We supplement our consolidated financial statements presented on a GAAP basis by providing an additional measure which may be considered a "non-GAAP" financial measure under applicable rules of the Securities and Exchange Commission. We believe that the disclosure of this non-GAAP financial measure provides our investors with additional information that reflects the amounts and financial basis upon which our management assesses and operates our business. These non-GAAP financial measures are not in accordance with generally accepted accounting principles and should not be viewed in isolation or as a substitute for reported, or GAAP, net income, and is not a substitute for, or superior to, measures of financial performance performed in conformity with GAAP.

"Non-GAAP net income" is not based on any standardized methodology prescribed by GAAP and represents GAAP net income adjusted to exclude (1) mark-to-market adjustments related to the fair value election for our investments in royalty rights presented in our earnings, which include the fair value re-measurement of future discounted cash flows for each of the royalty rights assets we have acquired, (2) market-to-mark adjustment to our equity affiliate, (3) non-cash interest revenue from notes receivable (4) non-cash stock-based compensation expense, (5) non-cash interest expense related to PDL debt offering costs, (6) mark-to-market adjustments related to warrants held, (7) non-cash amortization of intangible assets, (8) mark-to-market adjustment related to acquisition-related contingent consideration, (9) non-cash depreciation and amortization expense and (10) the related tax effect of all reconciling items within our reconciliation. Non-GAAP financial measures used by PDL may be calculated differently from, and therefore may not be comparable to, non-GAAP measures used by other companies.

View original content to download multimedia:http://www.prnewswire.com/news-releases/pdl-biopharma-reports-2019-third-quarter-financial-results-300953207.html

SOURCE PDL BioPharma, Inc.